Shares of Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $14.72, but opened at $14.21. Terumo shares last traded at $14.2427, with a volume of 1,217 shares.
Analyst Ratings Changes
Separately, Nomura upgraded shares of Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.
View Our Latest Report on Terumo
Terumo Price Performance
Terumo (OTCMKTS:TRUMY – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The business had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.84 billion. As a group, research analysts anticipate that Terumo Corp. will post 0.86 EPS for the current year.
Terumo Company Profile
Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.
Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.
See Also
- Five stocks we like better than Terumo
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
- Target’s Holiday Blitz: Slashing Prices to Capture Market Share
- NIO Inc.’s Geely Deal Is Really a Bet on Battery-Swap Network Utilization
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
